Venglustat (GZ402671) for Fabry Disease
This trial will study the effect of venglustat on neuropathic and abdominal pain symptoms of Fabry disease in adults who have not been treated or have been treated for less than 6 months.
- Fabry Disease
2 Primary · 12 Secondary · Reporting Duration: At 6 months and 12 months
2 Treatment Groups
1 of 2
1 of 2
114 Total Participants · 2 Treatment Groups
Primary Treatment: Venglustat (GZ402671) · Has Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 6 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What is Venglustat's (GZ402671) official regulatory status?
"Venglustat's (GZ402671) safety is estimated to be a 3. This Phase 3 rating means that, while there isn't extensive evidence of its efficacy, multiple rounds of testing have proven it to be safe." - Anonymous Online Contributor
Are there many hospitals conducting this trial in Canada?
"Currently, there are 7 clinical trial sites operational. These locations include Advent Health Orlando 301 East Princeton St_Site Number: 8400008 in Orlando, University of Manitoba, Children's Hospital Research Institute of Manitoba, Room 511C John Buhler Research Center - site number 1240002 in Winnipeg, and Oregon Health and Sciences University - site number 8400007 in Portland." - Anonymous Online Contributor
What is the projected number of people who will be taking part in this research project?
"In order to move this study forward, 114 individuals who match the pre-determined criteria must participate. Those willing and eligible can enroll at either Advent Health Orlando or University of Manitoba." - Anonymous Online Contributor